Skip to Content

Vertex Pharmaceuticals Inc VRTX

Morningstar Rating
$417.32 −1.14 (0.27%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Narrow-Moat Vertex's Diverse Pipeline Makes Significant Progress; CF Franchise Supports Growth

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, and Trikafta—will make the firm eligible to treat about 90% of the CF population, assuming international and pediatric approvals. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other rare indications to spur growth.

Price vs Fair Value

VRTX is trading at a 21% premium.
Price
$416.03
Fair Value
$385.00
Uncertainty
High
1-Star Price
$487.51
5-Star Price
$932.80
Economic Moat
Whqcvmc
Capital Allocation
Zyccvjkt

Bulls Say, Bears Say

Bulls

The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.

Bears

Vertex is highly dependent on the success of its cystic fibrosis franchise, and it could fail to diversify if its other pipeline candidates are not successful.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VRTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$418.46
Day Range
$412.65420.42
52-Week Range
$309.43443.82
Bid/Ask
$417.00 / $419.35
Market Cap
$107.80 Bil
Volume/Avg
72 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
27.42
Price/Sales
11.02
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.61%

Company Profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
5,400

Competitors

Valuation

Metric
VRTX
BMRN
ALNY
Price/Earnings (Normalized)
27.42106.79
Price/Book Value
6.123.37
Price/Sales
11.027.0210.55
Price/Cash Flow
28.5934.24206.48
Price/Earnings
VRTX
BMRN
ALNY

Financial Strength

Metric
VRTX
BMRN
ALNY
Quick Ratio
3.601.452.86
Current Ratio
3.992.513.08
Interest Coverage
86.388.78−3.36
Quick Ratio
VRTX
BMRN
ALNY

Profitability

Metric
VRTX
BMRN
ALNY
Return on Assets (Normalized)
19.46%6.15%−5.60%
Return on Equity (Normalized)
25.47%8.47%
Return on Invested Capital (Normalized)
21.34%6.27%−16.93%
Return on Assets
VRTX
BMRN
ALNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQkqfzkwjxBxdvd$571.0 Bil
REGN
Regeneron Pharmaceuticals IncNszbfbkBpyxlr$106.1 Bil
MRNA
Moderna IncDzwzsqjZfpfs$42.3 Bil
ARGX
argenx SE ADRBfctqzqbTygn$23.7 Bil
BNTX
BioNTech SE ADRNvqfpmrtZpqm$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncWqrzchngGmvppq$19.4 Bil
BMRN
Biomarin Pharmaceutical IncKjkzgcvFbmzpk$16.7 Bil
RPRX
Royalty Pharma PLC Class ARtcqxszdxqHcxps$13.6 Bil
INCY
Incyte CorpZshvxbbDzkjxf$12.8 Bil

Sponsor Center